ClinicalTrials.gg
CompletedNCT04400201Updated Aug 22, 2022

A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy

A Phase 3 interventional study of Remimazolam Tosilate and Propofol in Sedation, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-08-22.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

A multicenter, randomized, single-blind, active controlled, parallel group study comparing remimazolam tosilate to propofol in patients undergoing bronchoscopy.

02

Conditions studied

  • Sedation
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18\~80 years, female or male
  2. Patients scheduled for an bronchoscopy procedure
  3. 18 kg/m2\<\<30kg/m2
  4. Patients understand clearly and participate in the study voluntarily, and sign the

Exclusion criteria

Exclusion Criteria:

  1. Patients scheduled for emergency surgery
  2. Patients with a history of drug abuse and / or alcohol abuse 2 years prior to the screening period
  3. One or more of the laboratory findings fall out of the limitations for this study(,,,etc.);
  4. Pregnant women or those in lactation period
  5. Allergic to drugs used in the study
  6. Patients have participated in other clinical trial within the 3 months prior to randomization
  7. Any patient judged by the Principal Investigator (PI) or Sub-Investigator to be inappropriate for the subject for any other reason
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
330 participants (actual)

Study arms

  • Experimental
    Remimazolam Tosilate

    Drug: Remimazolam Tosilate

  • Active comparator
    Propofol

    Drug: Propofol

Interventions

  • Intravenous injection at a dose of 0.3mg/kg for sedation induction and continuous intravenous infusion at an initiative dose of 1 mg/kg/h for sedation maintenance.

  • Intravenous injection at a dose of 1.5\~2.5mg/kg for sedation induction and continuous intravenous infusion at the dose of 0\~12 mg/kg/h for sedation maintenance

06

What researchers measure

Primary outcomes

  1. Percentage (%) of participants who experienced successful sedation in undergoing bronchoscopy in each group

    Time frame: From the onset of administration of the study drug to removal of bronchoscope on Day 1 of treatment

Secondary outcomes

  1. Time from start of investigational medicinal product administration to loss of consciousness

    Time frame: From the onset of administration of the study drug to unconsciousness on Day 1 of treatment

  2. Time from stop of investigational medicinal product to MOAA/S Score=5

    Time frame: From the last dose of study drug until the patient has recovered to fully alert on Day 1 of treatment

  3. Time from stop of investigational medicinal product to Aldrete Score≥9

    Time frame: From the end of administration of the study drug until the patient reaches the modified Aldrete's system score of ≥9 points on Day 1 of treatment

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Oct 2020, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2020
First posted
May 22, 2020
StartActual
Jun 15, 2020
Primary completionActual
Oct 28, 2020
CompletionActual
Oct 30, 2020
Last update
Aug 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04400201
Responsible party
Sponsor
First posted
May 22, 2020
Start date
Jun 15, 2020
Primary completion
Oct 28, 2020
Completion
Oct 30, 2020
Last update
Aug 22, 2022

Study contacts

Peking Union Medical College Hospital
principal investigator · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remimazolam tosylate

Start the discussion